Chronix Biomedical

The test analyzes circulating cell-free DNA to gauge whether the patient is at high risk for prostate cancer and should go on to receive a biopsy.

NEW YORK (GenomeWeb News) – Similar to human breast cancers, canine mammary tumors are beset by chromosome instability, researchers from Chronix Biomedical and the Institute of Veterinary Medicine at the University of Göttingen in Germany reported in PLOS One yesterday.

Scientists from molecular diagnostics firm Chronix Biomedical and University Medical Center Göttingen in Germany have developed an assay to measure circulating cell-free graft DNA as an early indicator of organ transplant rejection.

At recent clinical meetings, two firms — Sequenta and Chronix Biomedical — presented data illustrating the distinct next-generation sequencing-based strategies each is taking to monitor minimal residual disease in cancer patients.

Chronix has yet to complete validation studies for its prostate, breast, and colon early detection cancer tests, so questions remain as to when the license will begin adding to Myriad's revenues.

Myriad has licensed the technology for early detection of breast, colon, and prostate cancers.

Chronix is developing a test based on its circulating DNA detection technology that will be tested in studies of how patients respond to Hemispherx's experimental drug Ampligen.

The grants, awarded through the Qualifying Therapeutic Discovery Project Program created by the Patient Protection and Affordable Care Act of 2010, were disclosed last week by the IRS.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.